Clinical Resistance to CDK4/6 Inhibitors: Why Cyclin E-CDK2 Is the Next Therapeutic Frontier
Trends in Oncology
Kayla Tyskiewicz
Clinical Resistance to CDK4/6 Inhibitors: Why Cyclin E-CDK2 Is the Next Therapeutic Frontier
Tell us about your study.
Talk to a study director about models, study design and timelines for your program.